CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Aurinia Pharmaceuticals Inc.

AUPH
$2.22B
Mid Cap
NASDAQPharmaceutical PreparationsπŸ‡ΊπŸ‡ΈNorth AmericaEDMONTON130 employees

Drugs in Pipeline

6

Phase 3 Programs

3

Upcoming Catalysts

1

Next Catalyst

Next month

Market Overview

Stock performance and key metrics

AUPH News
Catalyst Timeline

1 upcoming, 0 past

Market-Implied Move
Regulatory Approvals

Frequently asked questions

What is in Aurinia Pharmaceuticals Inc.'s drug pipeline?β†’

CatalystAlert tracks 6 drug candidates in Aurinia Pharmaceuticals Inc.'s (AUPH) pipeline across Phase 3, Phase 2. Its lead program is 0.05% Voclosporin Ophthalmic Solution (VOS) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Aurinia Pharmaceuticals Inc.'s next FDA catalyst?β†’

Aurinia Pharmaceuticals Inc.'s (AUPH) next tracked catalyst is a Earnings expected November 3, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track AUPH biotech catalysts?β†’

Add AUPH to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Aurinia Pharmaceuticals Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply